Update from the Canadian Dyspepsia Working Group.
Veldhuyzen van Zanten
S J
SJ
Flook
N
N
Chiba
N
N
Armstrong
D
D
Barkun
A
A
Bradette
M
M
Thomson
A
A
Bursey
F
F
Blackshaw
P
P
Frail
D
D
Sinclair
P
P
D002170:Canada; D020117:Cisapride / Q000009:adverse effects*; D004415:Dyspepsia / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology; D005764:Gastroesophageal Reflux / Q000188:drug therapy*; D005765:Gastrointestinal Agents / Q000009:adverse effects*; D006331:Heart Diseases / Q000139:chemically induced*; D006801:Humans; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D014481:United States; D014486:United States Food and Drug Administration
D005765:Gastrointestinal Agents; D020117:Cisapride